短期调控血浆游离脂肪酸不会改变瘦人和超重者骨骼肌中神经酰胺和葡萄糖神经酰胺的浓度。
Short-term manipulation of plasma free fatty acids does not change skeletal muscle concentrations of ceramide and glucosylceramide in lean and overweight subjects.
作者信息
Serlie M J, Meijer A J, Groener J E, Duran M, Endert E, Fliers E, Aerts J M, Sauerwein H P
机构信息
Department of Endocrinology and Metabolism, Laboratory of Endocrinology, Academic Medical Center F5-169, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
出版信息
J Clin Endocrinol Metab. 2007 Apr;92(4):1524-9. doi: 10.1210/jc.2006-2347. Epub 2007 Jan 30.
CONTEXT
Increased plasma free fatty acid (FFA) concentrations may be in part responsible for the increased levels of ceramide in skeletal muscle of obese subjects.
OBJECTIVE
We studied the effect of lowering and increasing plasma FFA levels on muscle ceramide and glucosylceramide concentrations in lean and obese subjects.
DESIGN
Plasma FFAs were either increased or decreased for 6 h by infusing a lipid emulsion or using Acipimox, respectively. Muscle biopsies were performed before and after the intervention for measurements of ceramide and glucosylceramide.
STUDY SUBJECTS
Eight lean [body mass index 21.9 (range, 19.6-24.6) kg/m2] and six overweight/obese [body mass index 34.4 (27.8-42.5) kg/m2] subjects without type 2 diabetes mellitus participated in the study.
MAIN OUTCOME MEASURE
Differences in muscle ceramide and glucosylceramide upon manipulation of plasma FFAs were measured.
RESULTS
There were no differences in muscle ceramide and glucosylceramide between lean and obese subjects, respectively. Increasing or decreasing plasma FFAs for 6 h had no effect on ceramide [high FFAs: 24 (19-25) vs. 24 (22-27) pmol/mg muscle, P=0.46; and 22 (20-28) vs. 24 (18-26) pmol/mg muscle, P=0.89 in lean and obese, respectively; low FFAs: 26 (24-35) vs. 23 (18-27) pmol/mg muscle, P=0.17 and 24 (15-44) vs. 24 (19-42) pmol/mg muscle, P=0.6 in lean and obese, respectively] and glucosylceramide [high FFAs: 2.0 (1.7-4.3) vs. 3.4 (2.1-4.6) pmol/mg muscle, P=0.17; and 3.0 (1.3-6.7) vs. 2.6 (1.2-3.9) pmol/mg muscle, P=0.89 in lean and obese, respectively; low FFAs: 2.2 (1.0-4.4) vs. 1.7 (1.4-3.0) pmol/mg muscle, P=0.92; and 6.6 (1.0-25.0) vs. 4.3 (1.3-7.6) pmol/mg muscle, P=0.7 in lean and obese, respectively] concentrations in skeletal muscle.
CONCLUSION
Short-term manipulation of plasma FFAs has no effect on ceramide and glucosylceramide concentrations in skeletal muscle from lean and obese subjects.
背景
血浆游离脂肪酸（FFA）浓度升高可能在一定程度上导致肥胖受试者骨骼肌中神经酰胺水平升高。
目的
我们研究了降低和升高血浆FFA水平对瘦人和肥胖受试者肌肉神经酰胺和葡萄糖神经酰胺浓度的影响。
设计
分别通过输注脂质乳剂或使用阿西莫司使血浆FFA水平升高或降低6小时。在干预前后进行肌肉活检以测量神经酰胺和葡萄糖神经酰胺。
研究对象
8名无2型糖尿病的瘦人[体重指数21.9（范围19.6 - 24.6）kg/m²]和6名超重/肥胖者[体重指数34.4（27.8 - 42.5）kg/m²]参与了本研究。
主要观察指标
测量血浆FFA水平改变后肌肉神经酰胺和葡萄糖神经酰胺的差异。
结果
瘦人和肥胖受试者的肌肉神经酰胺和葡萄糖神经酰胺水平分别无差异。血浆FFA水平升高或降低6小时对神经酰胺[高FFA：瘦人组24（19 - 25）对24（22 - 27）pmol/mg肌肉，P = 0.46；肥胖组22（20 - 28）对24（18 - 26）pmol/mg肌肉，P = 0.89；低FFA：瘦人组26（24 - 35）对23（18 - 27）pmol/mg肌肉，P = 0.17；肥胖组24（15 - 44）对24（19 - 42）pmol/mg肌肉，P = 0.6]和葡萄糖神经酰胺[高FFA：瘦人组2.0（范围1.7 - 4.3）对3.4（2.1 - 4.6）pmol/mg肌肉，P = 0.17；肥胖组3.0（1.3 - 6.7）对2.6（1.2 - 3.9）pmol/mg肌肉，P = 0.89；低FFA：瘦人组2.2（1.0 - 4.4）对1.7（1.4 - 3.0）pmol/mg肌肉，P = 0.92；肥胖组6.6（1.0 - 25.0）对4.3（1.3 - 7.6）pmol/mg肌肉，P = 0.7]在骨骼肌中的浓度均无影响。
结论
短期调节血浆FFA水平对瘦人和肥胖受试者骨骼肌中神经酰胺和葡萄糖神经酰胺浓度无影响。
Zotero 插件